公开(公告)号：KR1020160077644A

公开(公告)日：2016-07-04

申请号：KR1020140187789

申请日：2014-12-24

Applicant: 건국대학교 산학협력단

Inventor： 조쌍구 ,  김봉우 ,  최혜연

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61K31/7088 ,  C12Q1/6851 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/574

Abstract: 본발명은암 줄기-유사세포(CSLC:cancer stem like cell) 검출을위한바이오마커로서 GPR50 및이의용도에관한것으로, 보다구체적으로는 GPR50의폴리뉴클레오티드또는이의상보적폴리뉴클레오티드를포함하는암 줄기-유사세포(CSLC:cancer stem like cell) 검출을위한바이오마커용조성물, GPR50 유전자또는단백질억제제를유효성분으로포함하는항암용조성물, GPR50 유전자의발현수준또는상기유전자가코딩하는단백질의수준을측정하는방법을통한암의발병또는중증도를예측및 진단하는방법과암 치료제물질을스크리닝하는방법에관한것이다.

Abstract translation: 本发明涉及用于检测癌症干细胞（CSLC）的生物标志物GPR50及其用途，更具体地涉及包含GPR50和GPR50的互补多核苷酸的多核苷酸的检测CSLC的生物标志物组合物与包含GPR50基因的抗癌组合物 或蛋白质抑制剂作为活性成分的方法，通过测定GPR50基因的表达水平或由该基因编码的蛋白质的水平的方法，以及筛选癌症的方法来预测和诊断癌症的发生或严重程度的方法 处理剂材料。 本发明通过建立能够检测CSLC是否存在的生物标志物的GPR50的用途来实现对癌症的更根本的诊断和治疗的效果，从而使GPR50能够用于治疗具有药物耐受性的癌细胞， 预测癌症治疗后的癌症进展过程。

公开(公告)号：KR1020110055833A

公开(公告)日：2011-05-26

申请号：KR1020090112422

申请日：2009-11-20

Applicant: 건국대학교 산학협력단

Inventor： 조쌍구 ,  강근호 ,  이응룡

IPC: A61K31/37 ,  A61P35/02 ,  A61P35/00

Abstract: PURPOSE: A composition containing flavonoid for treating leukemia is provided to ensure strong effect for a patient with imatinib resistance. CONSTITUTION: A composition for treating leukemia contains 3-hydroxyflavone compounds as an active ingredient. The compound is analog or homolog of 3-hydroxyflavone compound. The composition additionally contains imatinib mesylate. A composition for treating imatinib resistant leukemia contains 3-hydroxyflavone compounds as an active ingredient and imatinib mesylate. A composition for treating anti-cancer drug resistant cancer contains 3-hydroxyflavone as an active ingredient.

Abstract translation: 目的：提供含有用于治疗白血病的黄酮类化合物的组合物，以确保对具有伊马替尼耐药性的患者的强烈作用。 构成：用于治疗白血病的组合物含有3-羟基黄酮化合物作为活性成分。 该化合物是3-羟基黄酮化合物的类似物或同系物。 该组合物另外含有甲磺酸伊马替尼。 用于治疗伊马替尼耐药白血病的组合物含有3-羟基黄酮化合物作为活性成分和甲磺酸伊马替尼。 用于治疗抗癌药物耐药性的组合物含有3-羟基黄酮作为活性成分。

公开(公告)号：KR1020100091762A

公开(公告)日：2010-08-19

申请号：KR1020090011111

申请日：2009-02-11

Applicant: 건국대학교 산학협력단

Inventor： 조쌍구 ,  김승우 ,  김정호 ,  최혜연 ,  김영봉 ,  김솔 ,  김정현 ,  이응룡 ,  정효순

IPC: A61K8/64 ,  A61K38/17 ,  A61Q19/00 ,  A61P17/18

Abstract: PURPOSE: A composition with antioxidation for skin protection is provided to proliferate skin cells and to inhibit oxidative reactive species(ROS) increase. CONSTITUTION: A composition for skin protection contains alpha-fetoprotein as an active ingredient. The alpha-fetoprotein has a sequence of sequence number 1. The alpha-fetoprotein is isolated from placenta or umbilical cord extracts. The extract of placenta or umbilical cord is obtain by homogenizeration. An antioxidative composition contains alpha-fetoprotein as an active ingredient.

Abstract translation: 目的：提供具有抗皮肤保护作用的组合物以增殖皮肤细胞并抑制氧化反应物质（ROS）增加。 构成：皮肤保护用组合物含有甲胎蛋白作为活性成分。 甲胎蛋白具有序列号1的序列。甲胎蛋白从胎盘或脐带提取物中分离。 通过均浆法获得胎盘或脐带提取物。 抗氧化组合物含有甲胎蛋白作为活性成分。

公开(公告)号：KR100812675B1

公开(公告)日：2008-03-13

申请号：KR1020060099919

申请日：2006-10-13

Applicant: 건국대학교 산학협력단

Inventor： 조쌍구 ,  박용선 ,  이훈택 ,  강용진 ,  김현정 ,  이응룡

IPC: A61K31/35 ,  A61P35/00

Abstract: A naringenin derivative is provided to be involved with controlling cell signal transmission, activity of activated oxygen species and cell cycle, thereby being widely used as a therapeutic agent of various cancers including large intestine cancer. A naringenin derivative controlling apoptosis is selected from the group consisting of 7-O-(m-methoxybenzyl) naringenin, 7-O-benzoxycarbonylmethyl naringenin, 7-O-benzylnaringenin, 7-O-(2-naphtylmethyl) naringenin, 7-O-(p-fluorobenzyl) naringenin and 7-O-(m-iodobenzyl) naringenin. A pharmaceutical composition for treating large intestine cancer comprises the naringenin derivative as an effective ingredient. A method for preparing the naringenin derivative comprises the steps of: (a) after putting naringenin and alkyl bromide in dimethylformamide, adding K2CO3 thereto and mixing it; (b) adding AcOEt to the mixture obtained from the step(a) and then dissolving it completely; (c) washing it with saline solution and drying; and (d) subjecting the product obtained from the step(c) to a silica gel chromatography for purifying it.

Abstract translation: 提供了柚皮素衍生物，用于控制细胞信号传导，活性氧活性和细胞周期，广泛用作各种癌症包括大肠癌的治疗剂。 控制细胞凋亡的柚皮苷衍生物选自7-O-（间甲氧基苄基）柚皮素，7-O-苯氧基羰基甲基柚皮素，7-O-苄基栀子腺苷，7-O-（2-萘甲基）柚皮素，7-O 柚皮素和7-（O-碘苄基）柚皮素。 用于治疗大肠癌的药物组合物包含柚皮素衍生物作为有效成分。 制备柚皮苷衍生物的方法包括以下步骤：（a）将柚皮素和烷基溴放入二甲基甲酰胺中，加入K 2 CO 3并混合; （b）将AcOEt加入到从步骤（a）获得的混合物中，然后完全溶解; （c）用盐水洗涤并干燥; 和（d）将由步骤（c）得到的产物进行硅胶色谱纯化。

公开(公告)号：KR100801960B1

公开(公告)日：2008-02-12

申请号：KR1020060111930

申请日：2006-11-14

Applicant: 건국대학교 산학협력단

Inventor： 조쌍구 ,  최용진 ,  정미영

IPC: C07K14/00

Abstract: An mRNA binding protein XaiF(xylanase activity increasing factor) is provided to increase the activity of xylanase by being expressed simultaneously with an xyn A, increase the transcription of exogenous genes when being used with a stem-loop structure where it is attached and a strong promoter, and inhibit the decomposition of transcript, thereby being usefully used for mass-producing exogenous proteins. A stem-loop structure where XaiF as an mRNA binding protein is attached consists of a sequence of SEQ ID : NO. 3 and is used for controlling the expression of a foreign gene. A cloning vector comprises the stem-loop structure. To over-express an exogenous protein, the XaiF as the mRNA binding protein and the stem-loop structure are used, wherein the mRNA binding protein combines the stem-loop structure with a strong gene promoter including a T7 promoter.

Abstract translation: 提供mRNA结合蛋白XaiF（木聚糖酶活性增加因子），以通过与xyn A同时表达来增加木聚糖酶的活性，当与其连接的茎 - 环结构一起使用时，增加外源基因的转录，并且强壮 启动子，并抑制转录物的分解，从而有效地用于批量生产外源蛋白质。 XaiF作为mRNA结合蛋白的茎环结构由序列SEQ ID NO： 3，用于控制外源基因的表达。 克隆载体包含茎 - 环结构。 为了过表达外源蛋白，使用XaiF作为mRNA结合蛋白和茎 - 环结构，其中mRNA结合蛋白将茎 - 环结构与包含T7启动子的强基因启动子结合。

公开(公告)号：KR100729732B1

公开(公告)日：2007-06-20

申请号：KR1020060005735

申请日：2006-01-19

Applicant: 건국대학교 산학협력단

Inventor： 조쌍구 ,  이응룡 ,  강용진

IPC: A61K31/35 ,  A61K31/352 ,  A61P17/16 ,  A61Q17/00

Abstract: 5,7,3',4'-Tetrahydoxy flavanone having protective effects on the UV(ultraviolet)-induced cell death in human keratinocytes is provided to inhibit apoptosis of human keratinocytes caused by UV by inhibiting production of reactive oxygen species due to UV in cells and activity reduction of p38 MAP(mitogen-activated protein) kinase through treating the human skin exposed to UV with the flavonoide. A composition for inhibiting apoptosis of human keratinocytes caused by UV comprises the 5,7,3',4'-tetrahydoxy flavanone represented by the formula(1) and isolated from the plant such as Viscum album var. as an effective ingredient, wherein the composition is a cosmetic or pharmaceutical composition and is formulated as granule, tablet, capsule, drink, cream or lotion. The daily dosage of 5,7,3',4'-tetrahydoxy flavanone is 0.1-1000 mg per adult.

Abstract translation: 本发明提供对人角质形成细胞中UV（紫外线）诱导的细胞死亡具有保护作用的5,7,3'，4'-四氢黄烷酮，通过抑制UV引起的活性氧的产生来抑制由UV引起的人角质形成细胞凋亡 通过用黄酮苷处理暴露于UV的人皮肤细胞和p38MAP（促分裂原活化蛋白）激酶的活性降低。 用于抑制由UV引起的人角质形成细胞凋亡的组合物包含由式（1）表示并从植物中分离的5,7,3'，4'-四氢氧基黄烷酮，例如槲寄生槲寄生（Viscum album var。 作为有效成分，其中所述组合物是化妆品或药物组合物并且配制成颗粒剂，片剂，胶囊剂，饮料，霜剂或洗剂。 5,7,3'，4'-四氢氧黄烷酮的每日剂量为每名成人0.1-1000mg。